Small molecule tyrosine kinase inhibitors in pancreatic cancer

Código QR

Small molecule tyrosine kinase inhibitors in pancreatic cancer

Sachin Gupta, Bassel F El-RayesDepartment of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, MI, USAAbstract: Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for advanced pancreatic cancer since 1996. Tyrosine kinas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sachin Gupta, Bassel F El-Rayes
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/bc8f52d5ed4b4a968040fa9cc7351cdc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen KS, et al.
Publicado: (2012)

Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.
por: Ramesh Narayanan, et al.
Publicado: (2013)

High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile
por: Mukthavaram R, et al.
Publicado: (2013)

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
por: Petrushev B, et al.
Publicado: (2016)

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
por: Sangyong Jung, et al.
Publicado: (2021)

Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
por: Raj Kumar Mongre, et al.
Publicado: (2021)

Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review
por: Tan BK, et al.
Publicado: (2021)

Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
por: Bin-Bin Li, et al.
Publicado: (2019)

Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
por: Ling-Ling Kong, et al.
Publicado: (2017)

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases
por: Marialuisa Moccia, et al.
Publicado: (2021)

Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System
por: Skubalova Z, et al.
Publicado: (2021)

Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer
por: Lucero-Acuña A, et al.
Publicado: (2014)

The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
por: Agnieszka Kaczmarska, et al.
Publicado: (2021)

The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
por: Weiguo Gu, et al.
Publicado: (2021)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: C. I. Edvard Smith, et al.
Publicado: (2021)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Ilana Schlam, et al.
Publicado: (2021)

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
por: Soonsil Hyun, et al.
Publicado: (2021)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Yundeok Kim, et al.
Publicado: (2021)

Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
por: Nicholas M Levinson, et al.
Publicado: (2012)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Paula Aldaz, et al.
Publicado: (2021)

An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies
por: Alison Findlay, et al.
Publicado: (2021)

Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
por: Mohamed A. Ismail, et al.
Publicado: (2021)

Erlotinib in the treatment of advanced pancreatic cancer
por: Robin K Kelley, et al.
Publicado: (2008)

Multi-small molecule conjugations as new targeted delivery carriers for tumor therapy
por: Shan L, et al.
Publicado: (2015)

ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί
por: Jeon-Soo Lee, et al.
Publicado: (2021)

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
por: Jeet Gandhi, et al.
Publicado: (2009)

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
por: Patrice Dubreuil, et al.
Publicado: (2009)

Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket.
por: Diane D'allard, et al.
Publicado: (2013)

Small molecule PZL318: forming fluorescent nanoparticles capable of tracing their interactions with cancer cells and activated platelets, slowing tumor growth and inhibiting thrombosis
por: Li S, et al.
Publicado: (2015)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
por: Lee CS, et al.
Publicado: (2020)

Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
por: Hong-bing Liu, et al.
Publicado: (2013)

Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models
por: Feng Q, et al.
Publicado: (2021)

THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE
por: Mohammad Abu-Tineh, et al.
Publicado: (2021)

Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia
por: Brittany M. Duggan, et al.
Publicado: (2017)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
por: Zaharie F, et al.
Publicado: (2015)

Identification of small molecule inhibitors of Interleukin-18
por: Brian Krumm, et al.
Publicado: (2017)

Tyrosine Hydroxylase Expression is Associated with Bone Marrow Infiltration in Neuroblastoma Patients
por: Samar El-Shazly, et al.
Publicado: (2021)

Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met
por: Tahereh Damghani, et al.
Publicado: (2021)

Reprogramming signal transduction through a designer receptor tyrosine kinase
por: Tatphon Kongkrongtong, et al.
Publicado: (2021)

Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1
por: Onisha Patel, et al.
Publicado: (2021)